Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Simak Ali
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design - Nature Communications
Abstract Rational design of next-generation therapeutics can be facilitated by high-resolution structures of drug targets bound to small-molecule inhibitors. However, application of structure-based methods to macromolecules refractory to crystallization has been hampered by the often-limiting resolution and throughput of cryogenic electron microscopy (cryo-EM).
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer - British Journal of Cancer
Correction to: British Journal of Cancer (2023) 128:2326-2337; https://doi.org/10.1038/s41416-023-02252-8, Article published online 19 April 2023 Following the original publication, the authors were notified of an error present in Figure 1, specifically Figure 1bii, where the same image file was used for CDK4 and CDK7. The corrected version of Figure 1 is produced here. The authors provided the journal with the original data.
Selective inhibition of CDK9 in triple negative breast cancer - Oncogene
Abstract Targeted therapy for triple-negative breast cancers (TNBC) remains a clinical challenge due to tumour heterogeneity. Since TNBC have key features of transcriptionally addicted cancers, targeting transcription via regulators such as cyclin-dependent kinase 9 (CDK9) has potential as a therapeutic strategy. Herein, we preclinically tested a new selective CDK9 inhibitor (CDDD11-8) in TNBC using cell line, patient-derived organoid, and patient-derived explant models.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib | Nature Communications
Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In this article the author name R. C. Coombes was incorrectly written as R. Charles Coombes. The original article has been corrected. Author information Authors and Affiliations Imperial College, South Kensington, London, UK R. C.
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib - Nature Communications
The study was approved by the regulatory authorities, the Yorkshire & The Humber - Leeds West Research Ethics Committee, Jarrow, UK and the local ethics committees for each site. The study was conducted in accordance with ICH-GCP guidelines, the Declaration of Helsinki and all legal, regulatory, and data protection requirements. All patients provided written informed consent prior to participation.
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer - British Journal of Cancer
Abstract Background Current strategies to inhibit androgen receptor (AR) are circumvented in castration-resistant prostate cancer (CRPC). Cyclin-dependent kinase 7 (CDK7) promotes AR signalling, in addition to established roles in cell cycle and global transcription, providing a rationale for its therapeutic targeting in CRPC. Methods The antitumour activity of CT7001, an orally bioavailable CDK7 inhibitor, was investigated across CRPC models in vitro and in xenograft models in vivo.
Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer - British Journal of Cancer
Abstract Background We report copy-number profiling by low-pass WGS (LP-WGS) in individual circulating tumour cells (CTCs) for guiding treatment in patients with metastatic breast cancer (MBC), comparing CTC results with mutations detected in circulating tumour DNA (ctDNA) in the same blood samples.
Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence - Nature Communications
Abstract More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER+). A clinical challenge of ER+ BC is that they can recur decades after initial treatments. Mechanisms governing latent disease remain elusive due to lack of adequate in vivo models.
2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942
Abstract The human CDK-activating kinase (CAK), composed of CDK7, cyclin H, and MAT1, is involved in the control of transcription initiation and the cell cycle. Because of these activities, it has been identified as a promising target for cancer chemotherapy. A number of CDK7 inhibitors have entered clinical trials, among them ICEC0942 (also known as CT7001). Structural information can aid in improving the affinity and specificity of such drugs or drug candidates, reducing side effects in patients.
90 Years of progesterone: Ninety years of progesterone: the ‘other’ ovarian hormone
The beginning of the twentieth century saw a transformation in the field of endocrinology. Prominent among the many seminal discoveries was the identification and subsequent purification of ovarian steroid hormones, estrogen and progesterone. It is wholly 90 years since the first report of the isolation and characterisation of progesterone by Willard M. Allen and George W. Corner (Corner & Allen 1929).
Author Correction: The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Simak
Contact Simak, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack